VRML, Vermillion, Inc.

** VRML reported that it has received a notice of allowance from the United States Patent and Trademark Office for a patent, "Biomarkers for Ovarian Cancer."

The patent makes claims in the uses of a urinary Small MBL-associated protein C-terminal fragment (sMAP) in the diagnosis of ovarian cancer, ovarian cancer monitoring, and patient management.

This represents the fifteenth biomarker patent granted or allowed for VRML, four of which support the company's ovarian cancer franchise and its flagship product, OVA1(R).

OVA1 is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using a unique multi-biomarker approach.

In a published clinical trial, OVA1 achieved 99% sensitivity in detecting epithelial ovarian cancers (EOC). This included 96% sensitivity for stage I EOC, the earliest and most curable EOC stage, compared with 57% for the conventional biomarker CA125. In addition, OVA1 found 70% of malignancies missed by non-specialist pre-surgical assessment, and it increased detection of malignancy over ACOG guidelines from 77% to 94%.

As the first protein-based, In Vitro Diagnostic Multi-Variate Index Assay (IVDMIA) cleared by the FDA, OVA1 also represents a new class of software-based diagnostics.

VRML is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients.

More about VRML at www.vermillion.com

**********************

DRJ, Dreams, Inc.

** DRJ reported that it has signed a definitive merger agreement with Fanatics, Inc., a leading online seller of licensed sports products.

The agreement calls for Fanatics to acquire all the outstanding shares of DRJ for $3.45 per share in cash for an aggregate transaction value of approximately $183 million, taking into account $25 million of outstanding debt.

DRJ is a technology driven, multi-channel retailer focused on the sports licensed products industry.

More about DRJ at www.Dreamscorp.com.

**********************

The advantages of Internet marketing are many. Since the World Wide Web is so widely available, businesses can access millions of potential customers with just a few clicks of their mouse.

Crown Equity Holdings Inc. (CRWE.OB) offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them.

CRWE?s division CRWE AD-Services (www.crwe-adservices.com), is a full service multimedia advertising company specializing in internet marketing. It provides modern and unique advertising campaigns, dedicated to offering the most cost effective advertising solutions.

The Web is not just nationwide - it's worldwide. This means that your product or service can be viewed by people just about anywhere in the world.

CRWE?s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.

More about CRWE at www.crownequityholdings.com.

**********************

ECYT, Endocyte Inc.

** Merck, known as MSD outside the United States and Canada, and ECYT reported that they have entered into an agreement to develop and commercialize ECYT's novel investigational therapeutic candidate vintafolide (EC145).

Vintafolide is currently being evaluated in a Phase III clinical trial for platinum-resistant ovarian cancer, (PROCEED trial) and a Phase II trial for non-small cell lung cancer (NSCLC); both studies are also using ECYT's investigational companion diagnostic agent, etarfolatide (EC20).

Under the agreement, Merck, through a subsidiary, will gain worldwide rights to develop and commercialize vintafolide. ECYT will receive a $120 million upfront payment and is eligible for milestone payments of up to $880 million based on the successful achievement of development, regulatory and commercialization goals for vintafolide for a total of six cancer indications.

In addition, if vintafolide receives regulatory approval, ECYT will receive an equal share of the profit in the United States (U.S.) as well as a double digit percentage royalty on sales of the product in the rest of the world. ECYT has retained the right to co-promote vintafolide with Merck in the U.S. and Merck has the exclusive right to promote vintafolide in the rest of world.

ECYT will be responsible for the majority of funding and completion of the PROCEED trial. Merck will be responsible for all other development activities and costs and have all decision rights for vintafolide. ECYT remains responsible for the development, manufacture and commercialization worldwide of etarfolatide, a non-invasive companion diagnostic imaging agent that is used to identify folate receptor positive tumor cells.

ECYT has completed three single arm studies of vintafolide in patients with advanced platinum resistant ovarian cancer, non-small cell lung cancer and solid tumors. In a randomized Phase II clinical trial (PRECEDENT) comparing vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD alone in women with platinum-resistant ovarian cancer, vintafolide demonstrated a statistically significant delay in disease progression or death in the overall population, with the largest improvement observed in patients with all tumors imaged as positive for folate receptor expression utilizing etarfolatide.

The European Union had granted orphan drug status to vintafolide, and ECYT plans to file a marketing authorization application in the third quarter of 2012.

ECYT is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases.

More about ECYT at www.endocyte.com.

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.